The collaboration between Sanofi and Kymera Therapeutics on SAR444656 may represent a significant opportunity for competition ...

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients ...

A doctor can also review your treatment plan if existing dermatitis becomes widespread or isn’t getting better. Read on to learn more about the types and symptoms of dermatitis. This article ...

Shaperon secures phase 2 trials for atopic dermatitis treatment Nugel after positive review Shaperon obtains approval for ...

Within the atopic dermatitis (AD) field, Sanofi has been developing the IRAK4 degrader SAR444656 (KT-474) in collaboration ...

Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.

Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

The dermatitis began approximately 3 years prior to presentation, shortly after the use of over-the-counter vaginal suppositories for treatment of a presumed yeast infection. Prior treatments ...

Shaperon successfully completed part 1 of the multinational phase 2 clinical trial of 'HY209 gel' targeting patients with ...

Treatment options include a variety of medications ... approximately 50 cases of autoimmune progesterone dermatitis (APD) have been documented. Because of the limited number of reported cases ...